imagine buying at 2.75 then selling at 5 later on , and...

imagine buying at 2.75 then selling at 5 later on , and specially that there isn't many shares left to buy any way . read the last announcement again don't let any one fool , how many asx listed company have a drug manufacturing facility and international business worth FY24 EBITDA so back to cash generation again . sell now if you like . you selling at %50 discounted price . now they bought rhofade adds 15 m to the revenue , Bijuvea adds another 15 m , doxycyline and so on . and nextstellis still have a big potential . how do you know they will not announce another drug deal that will add another 150 m to the revenue because they still cashed up . the strategy is adding products with accretive value and to leverage existing infrastructure which means any product they add will not incur any sales and marketing expense it will be using the existing team and so on . slowly building the revenue back to where it was , CDMO in Australia , they just got a government allowance a couple million dollars